PepGen (PEPG) Insider Howard Mayer Buys 34,000 Shares

Howard Mayer, an insider at PepGen Inc., bought 34,000 shares of the company on June 18. This transaction comes as PepGen, trading under the ticker PEPG on the NasdaqGS, was priced at $1.79 on Tuesday.

Insider Buying and Selling at PepGen Inc.

Several insiders, including Howard Mayer, purchased 34,000 shares each on June 18, without a pre-planned schedule. This activity indicates potential confidence in the company's future.

Other Institutional Activity in PepGen Inc.

Institutional investors have been actively adjusting their positions in PepGen Inc. Millennium Management LLC significantly increased its stake by 1,881,200 shares, bringing its total to 2,079,143 shares, valued at about $3.68 million. Similarly, Commodore Capital LP added 1,075,000 shares to hold 4,475,000 shares worth approximately $7.92 million, marking a 31.6% increase. Laurion Capital Management LP also increased its holdings by 698,722 shares, ending with 2,750,855 shares valued at $4.87 million.

PepGen Inc. Stock Down 35.8%

Shares of PepGen Inc. traded near $1.79 on Tuesday. The company has a market cap of $123.8 million and a forward P/E ratio of -1.46, as it is not currently profitable. Its beta is 1.927, indicating higher volatility compared to the market. Over the past year, the stock has ranged from a low of $1.01 to a high of $7.80, with a 50-day moving average of $1.60 and a 200-day moving average of $4.05.

Analysts Set New Price Targets

Analyst firms have been active in setting new price targets for PepGen Inc. On June 16, Craig-Hallum initiated coverage with a buy rating and an $11.00 price target. Wedbush maintained its buy rating with a $4.00 target on May 13. Overall, analysts maintain a strong buy consensus with a mean target price of $10.25, based on eight opinions.

About PepGen Inc.

PepGen Inc. is a biotechnology company based in Boston, Massachusetts. Founded in 2018, it focuses on developing oligonucleotide therapeutics to treat severe neuromuscular and neurologic diseases. The company is advancing its lead candidate, PGN-EDODM1, in a Phase 2 trial for myotonic dystrophy type 1. PepGen is led by CEO Dr. James G. McArthur and employs 59 people.

Bottom Line

Howard Mayer's purchase of PepGen shares, along with insider and institutional buying, suggests confidence in the company's prospects. Investors should note that 13F filings and insider transactions are backward-looking and may not reflect current positions. PepGen remains a stock to watch in the biotechnology sector, with ongoing clinical trials and strong analyst support.